KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) Return on Sales (2019 - 2025)

Esperion Therapeutics (ESPR) has disclosed Return on Sales for 7 consecutive years, with 0.37% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Sales rose 67.0% year-over-year to 0.37%, compared with a TTM value of 0.06% through Dec 2025, down 5.0%, and an annual FY2025 reading of 0.06%, up 10.0% over the prior year.
  • Return on Sales was 0.37% for Q4 2025 at Esperion Therapeutics, up from 0.37% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.42% in Q1 2024 and bottomed at 11.4% in Q1 2021.
  • Average Return on Sales over 5 years is 2.17%, with a median of 1.52% recorded in 2023.
  • The sharpest move saw Return on Sales soared 3133bps in 2021, then plummeted -246bps in 2022.
  • Year by year, Return on Sales stood at 4.48% in 2021, then skyrocketed by 33bps to 3.02% in 2022, then soared by 41bps to 1.78% in 2023, then soared by 83bps to 0.3% in 2024, then soared by 223bps to 0.37% in 2025.
  • Business Quant data shows Return on Sales for ESPR at 0.37% in Q4 2025, 0.37% in Q3 2025, and 0.16% in Q2 2025.